The executive chief of the European Union has said that the EU will donate a further 200 million COVID-19 vaccine doses to poorer countries and close gaps in its own vaccination coverage, Reuters news agency reported on Wednesday.
Ursula von der Leyen was quoted as telling the European Parliament in a speech in that the EU's first pandemic priority was to speed up global vaccination, given less than 1% of doses globally administered had been in low-income countries.
She said that European Commission will donate 200 million COVID-19 vaccine doses to low-income countries by the middle of next year, on top of the 250 million doses already pledged.
The European Commission president also said she saw "worrisome divergences" between the rates of vaccination in EU member states, adding that the bloc had secured 1.8 billion further vaccine doses to cover more initial and booster shots.
Von der Leyen added that the EU was setting up a health emergency response authority, designed to improve the bloc's response to cross-border health threats.
She also proposed that the EU invest EUR50bn by 2027 to improve its preparedness and resilience to future health threats.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return